Clinical and experimental oncology and immunology
Host Department
Department of Surgery, Oncology and Gastroenterology
Clinical and experimental oncology and immunology
Research Topic B
Abstract of the proposed UNIPhD research project
Retrovirus human T-lymphotropic virus type 1 (HTLV-1) causes an aggressive neoplasm of CD4+ T-cells termed adult T-cell leukemia/lymphoma(ATLL), that arises from the yet incompletely understood interplay that leads to T-cell immortalization. To date, there is no vaccine available to protect against HTLV-1 infection. Studies revealed alterations in the expression of many miRNAs in HTLV-1-infected cells that play roles in the viral life cycle, suggesting that miRNAs could be exploited as anti-HTLV-1 drugs. In addition, studies from the UniPD host lab indicated that selective killing of HTLV-1-infected cells can be obtained with ROS. We will examine the possible ability of miRNAs and ROS-inducing drugs to eliminate HTLV-1-infected cells. miRNAs and drugs will be delivered to cells by encapsulating them in particles conjugated with an antibody against CADM1-highly expressed on the surface of HTLV-1-infected cells-.
Short bio
She is a second-year Ph.D. student at UNIPD with a Master’s in Hematology and Blood Banking from Tehran, Iran, and a B.Sc. in Clinical Laboratory Science. Passionate about translating innovative ideas into practical solutions, her focus is on Hematology and Oncology. Committed to making meaningful contributions, she aims to advance medical knowledge and work towards finding cures for patients battling cancer.
